SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 1, 2019
ZIVO BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
2804 Orchard Lake Road, Suite 202, Keego Harbor, Michigan 48320
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (248) 452-9866
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On May 1, 2019 the Company released the President’s Report To Shareholders dated May 1, 2019, a copy of which is filed herewith as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
Exhibit 99.1 – President’s Report to Shareholders dated May 1, 2019.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTH ENHANCEMENT PRODUCTS, INC.
Date: May 1, 2019
By: /s/ PHILIP M, RICE II
Philip M. Rice, II,
Chief Financial Officer